Rigel Pharmaceuticals, Inc. (RIGL)
-NasdaqGS 4.58 
0.16(3.38%) 4:00PM EDT
| Prev Close: | 4.74 |
|---|
| Open: | 4.71 |
|---|
| Bid: | 4.58 x 2100 |
|---|
| Ask: | 4.62 x 800 |
|---|
| 1y Target Est: | 7.83 |
|---|
| Beta: | 0.95 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 4.57 - 4.74 |
|---|
| 52wk Range: | 4.41 - 11.44 |
|---|
| Volume: | 781,247 |
|---|
| Avg Vol (3m): | 879,787 |
|---|
| Market Cap: | 399.10M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 17)
- RIGEL PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 14)
- 3 Drug Catalysts to Watch in 2013at Motley Fool(Thu, May 9)
- RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Tue, May 7)
- Rigel Announces First Quarter 2013 Financial ResultsPR Newswire(Tue, May 7)
- RIGEL PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 7)
- April's Unhealthiest Stocksat Motley Fool(Sat, May 4)
- Rigel Pharmaceuticals Becomes Oversold (RIGL)at TheStreet(Fri, May 3)
- 3 Biggest Biotech Crashes in Aprilat Motley Fool(Thu, May 2)
- Expert Analyst Ian Somaiya Discusses the Decline in European Drug Pricing with The Wall Street Transcript; Models a 1% to 2% Annual Decline in Price for Companies That Sell OverseasWall Street Transcript(Tue, Apr 30)
- 5 Health Care Stocks Under $10 Ready to Rip Higherat TheStreet(Thu, Apr 18)
- 5 Stocks Poised for Breakoutsat TheStreet(Fri, Apr 12)
- AZN Reports Data on FostamatinibZacks(Mon, Apr 8)
- Small Pharma Watch List: Week Of April 8, 2013at Seeking Alpha(Mon, Apr 8)
- Why Rigel Is Poised to Bounce Backat Motley Fool(Mon, Apr 8)
Key Statistics
| Forward P/E (1 yr): | 41.64 |
|---|
| P/S (ttm): | 275.36 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.03 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.30 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.
View More